![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: RPRD2 |
Gene summary for RPRD2 |
![]() |
Gene information | Species | Human | Gene symbol | RPRD2 | Gene ID | 23248 |
Gene name | regulation of nuclear pre-mRNA domain containing 2 | |
Gene Alias | HSPC099 | |
Cytomap | 1q21.2 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | Q5VT52 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
23248 | RPRD2 | CCI_1 | Human | Cervix | CC | 1.53e-14 | 1.39e+00 | 0.528 |
23248 | RPRD2 | CCI_2 | Human | Cervix | CC | 2.78e-09 | 9.94e-01 | 0.5249 |
23248 | RPRD2 | CCI_3 | Human | Cervix | CC | 4.42e-14 | 9.58e-01 | 0.516 |
23248 | RPRD2 | A001-C-207 | Human | Colorectum | FAP | 5.75e-03 | -2.10e-01 | 0.1278 |
23248 | RPRD2 | A015-C-203 | Human | Colorectum | FAP | 4.35e-26 | -3.97e-01 | -0.1294 |
23248 | RPRD2 | A015-C-204 | Human | Colorectum | FAP | 6.27e-06 | -2.87e-01 | -0.0228 |
23248 | RPRD2 | A014-C-040 | Human | Colorectum | FAP | 5.82e-04 | -3.79e-01 | -0.1184 |
23248 | RPRD2 | A002-C-201 | Human | Colorectum | FAP | 1.32e-13 | -3.92e-01 | 0.0324 |
23248 | RPRD2 | A002-C-203 | Human | Colorectum | FAP | 9.63e-03 | -1.40e-01 | 0.2786 |
23248 | RPRD2 | A001-C-108 | Human | Colorectum | FAP | 2.38e-14 | -2.78e-01 | -0.0272 |
23248 | RPRD2 | A002-C-205 | Human | Colorectum | FAP | 7.55e-21 | -4.56e-01 | -0.1236 |
23248 | RPRD2 | A001-C-104 | Human | Colorectum | FAP | 2.01e-03 | -2.25e-01 | 0.0184 |
23248 | RPRD2 | A015-C-005 | Human | Colorectum | FAP | 4.51e-03 | -2.10e-01 | -0.0336 |
23248 | RPRD2 | A015-C-006 | Human | Colorectum | FAP | 1.28e-14 | -5.44e-01 | -0.0994 |
23248 | RPRD2 | A015-C-106 | Human | Colorectum | FAP | 7.32e-09 | -2.84e-01 | -0.0511 |
23248 | RPRD2 | A002-C-114 | Human | Colorectum | FAP | 8.48e-16 | -3.61e-01 | -0.1561 |
23248 | RPRD2 | A015-C-104 | Human | Colorectum | FAP | 3.17e-28 | -4.61e-01 | -0.1899 |
23248 | RPRD2 | A001-C-014 | Human | Colorectum | FAP | 3.29e-17 | -3.80e-01 | 0.0135 |
23248 | RPRD2 | A002-C-016 | Human | Colorectum | FAP | 4.91e-23 | -3.43e-01 | 0.0521 |
23248 | RPRD2 | A015-C-002 | Human | Colorectum | FAP | 1.26e-12 | -4.98e-01 | -0.0763 |
Page: 1 2 3 4 5 6 7 8 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | ![]() |
Oral cavity | LP | ![]() |
Oral cavity | EOLP | ![]() |
Oral cavity | NEOLP | ![]() |
Esophagus | HGIN | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003112412 | Esophagus | ESCC | mRNA 3'-end processing | 47/8552 | 62/18723 | 1.29e-06 | 1.58e-05 | 47 |
GO:00311233 | Esophagus | ESCC | RNA 3'-end processing | 76/8552 | 116/18723 | 1.25e-05 | 1.15e-04 | 76 |
GO:00311241 | Liver | HCC | mRNA 3'-end processing | 50/7958 | 62/18723 | 8.44e-10 | 2.60e-08 | 50 |
GO:00311231 | Liver | HCC | RNA 3'-end processing | 81/7958 | 116/18723 | 2.27e-09 | 6.32e-08 | 81 |
GO:00311242 | Oral cavity | OSCC | mRNA 3'-end processing | 49/7305 | 62/18723 | 1.40e-10 | 4.14e-09 | 49 |
GO:00311232 | Oral cavity | OSCC | RNA 3'-end processing | 75/7305 | 116/18723 | 1.93e-08 | 3.79e-07 | 75 |
GO:00311235 | Thyroid | PTC | RNA 3'-end processing | 65/5968 | 116/18723 | 6.24e-08 | 1.30e-06 | 65 |
GO:00311245 | Thyroid | PTC | mRNA 3'-end processing | 40/5968 | 62/18723 | 1.28e-07 | 2.48e-06 | 40 |
GO:003112312 | Thyroid | ATC | RNA 3'-end processing | 65/6293 | 116/18723 | 5.58e-07 | 7.93e-06 | 65 |
GO:003112413 | Thyroid | ATC | mRNA 3'-end processing | 40/6293 | 62/18723 | 6.25e-07 | 8.65e-06 | 40 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
RPRD2 | SNV | Missense_Mutation | novel | c.443N>G | p.Thr148Ser | p.T148S | Q5VT52 | protein_coding | tolerated_low_confidence(0.18) | benign(0.011) | TCGA-3C-AALI-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Poly E | Complete Response |
RPRD2 | SNV | Missense_Mutation | novel | c.3275G>T | p.Ser1092Ile | p.S1092I | Q5VT52 | protein_coding | deleterious_low_confidence(0) | benign(0.054) | TCGA-A2-A0EP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
RPRD2 | SNV | Missense_Mutation | novel | c.3706N>G | p.Pro1236Ala | p.P1236A | Q5VT52 | protein_coding | deleterious_low_confidence(0) | benign(0.001) | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD |
RPRD2 | SNV | Missense_Mutation | c.1123G>T | p.Asp375Tyr | p.D375Y | Q5VT52 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.986) | TCGA-AR-A1AR-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unspecific | Docetaxel | PD | |
RPRD2 | deletion | In_Frame_Del | novel | c.2878_2883delAAGCAG | p.Lys960_Gln961del | p.K960_Q961del | Q5VT52 | protein_coding | TCGA-A2-A3XT-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | PR | ||
RPRD2 | insertion | Frame_Shift_Ins | novel | c.3704_3705insCAGAGAG | p.Pro1236ArgfsTer47 | p.P1236Rfs*47 | Q5VT52 | protein_coding | TCGA-AO-A0JD-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
RPRD2 | insertion | In_Frame_Ins | novel | c.1383_1384insGATTCTCGTGTCTCAGCCTCTGTAGTAGCTGGG | p.Ser461_Ser462insAspSerArgValSerAlaSerValValAlaGly | p.S461_S462insDSRVSASVVAG | Q5VT52 | protein_coding | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
RPRD2 | SNV | Missense_Mutation | novel | c.381G>T | p.Trp127Cys | p.W127C | Q5VT52 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.887) | TCGA-C5-A2M1-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
RPRD2 | SNV | Missense_Mutation | rs748820473 | c.3469G>A | p.Gly1157Arg | p.G1157R | Q5VT52 | protein_coding | deleterious_low_confidence(0) | benign(0.344) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
RPRD2 | SNV | Missense_Mutation | c.1060G>A | p.Glu354Lys | p.E354K | Q5VT52 | protein_coding | tolerated_low_confidence(0.21) | benign(0) | TCGA-Q1-A73O-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |